Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 7/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646850 | 0.87 | IDO1 (0.42) | IDO1ACHE | |
| SCHEMBL23977863 | 0.82 | IDO1 (0.58) | IDO1MAOBTAAR1MAOAACHE | |
| SCHEMBL19240343 | 0.80 | ENPP2 (0.50) | TAAR1LMNA | |
| SCHEMBL6667381 | 0.79 | IDO1 (0.69) | IDO1MAOBTAAR1MAOAACHE | |
| SCHEMBL22021921 | 0.79 | TACR1 (0.38) | IDO1 | |
| SCHEMBL14115730 | 0.78 | MRGPRX4 (0.49) | IDO1MAOB | |
| SCHEMBL22173456 | 0.78 | IDO1 (0.36) | IDO1ACHE | |
| SCHEMBL13597426 | 0.78 | IDO1 (0.58) | IDO1MAOBTAAR1MAOA | |
| SCHEMBL19889112 | 0.78 | TRPA1 (0.38) | IDO1MAOBACHE | |
| SCHEMBL19354065 | 0.78 | IDO1 (0.36) | IDO1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021155264-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-10793514-B2 | Glutamine transport inhibitors and methods for treating cancer | VANDERBILT UNIVERSITY (US) | 2020-10-06 | — | — | US | disclosed |
| US-10647683-B2 | Hsp70 modulators and methods for making and using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-05-12 | — | — | US | disclosed |
| US-20200095190-A1 | Glutamine Transport Inhibitors and Methods for Treating Cancer | VANDERBILT UNIVERSITY | 2020-03-26 | — | — | US | disclosed |
| CN-110183352-A | β-carbonyl-(alpha-cyano imines) class compound and its synthetic method | 上海大学 | 2019-08-30 | — | — | CN | disclosed |
| US-20190241526-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2019-08-08 | — | — | US | disclosed |
| US-20180170883-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | MEMORIAL SLOAN KETTERING CANCER CENTER | 2018-06-21 | — | — | US | disclosed |
| US-9878987-B2 | HSP70 modulators and methods for making and using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878987-B2 | HSP70 modulators and methods for making and using the same | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170247339-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2017-08-31 | — | — | US | disclosed |
| US-20140343054-A1 | Therapeutic Use of Imidazopyridine Derivatives | SANOFI (FR) | 2014-11-20 | — | — | US | disclosed |
| US-20140243328-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-08-28 | — | — | US | disclosed |
| US-8759344-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-06-24 | — | — | US | disclosed |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
| US-8119653-B2 | Belactosin derivatives as therapeutic agents/biological probes and their synthesis | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-02-21 | — | — | US | disclosed |
| US-8114893-B2 | Compounds and methods of use | GENENTECH, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100179190-A1 | BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20090042922-A1 | NOVEL BELACTOSIN DERIVATIVES AS THERAPEUTIC AGENTS/BIOLOGICAL PROBES AND THEIR SYNTHESIS | NATIONAL SCIENCE FOUNDATION | 2009-02-12 | — | — | US | disclosed |
| US-7473783-B2 | Bicyclic pyrazolo protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179190-A1 | BICYCLIC PYRAZOLO PROTEIN KINASE MODULATORS | MAP3K20, MAP4K2, MAP4K3 | IDO1 3282/4885MAOB 3489/4885TAAR1 3313/4885 |
| US-20190241526-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | HSPA2, HSP90AA1, HSP90AB1 | IDO1 1909/4885MAOB 2862/4885TAAR1 4067/4885 |
| US-20140243328-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, ENY2, PAH | IDO1 812/4885MAOB 178/4885TAAR1 3200/4885 |
| US-20200095190-A1 | Glutamine Transport Inhibitors and Methods for Treating Cancer | SLC1A5, SLC7A11, SLC3A2 | IDO1 2036/4885MAOB 2702/4885TAAR1 3015/4885 |
| US-20140343054-A1 | Therapeutic Use of Imidazopyridine Derivatives | CCNY, UTS2R, WNK2 | IDO1 1048/4885MAOB 1788/4885TAAR1 2409/4885 |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, ENY2, PAH | IDO1 812/4885MAOB 178/4885TAAR1 3200/4885 |
| US-20170247339-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | WEE1, WEE2, EGFR | IDO1 751/4885MAOB 3811/4885TAAR1 4530/4885 |
| US-20180170883-A1 | HSP70 MODULATORS AND METHODS FOR MAKING AND USING THE SAME | HSPA2, HSP90AA1, HSP90AB1 | IDO1 1909/4885MAOB 2862/4885TAAR1 4067/4885 |
| US-20090042922-A1 | NOVEL BELACTOSIN DERIVATIVES AS THERAPEUTIC AGENTS/BIOLOGICAL PROBES AND THEIR SYNTHESIS | PSMB1, PSMB10, PBK | IDO1 772/4885MAOB 1853/4885TAAR1 4060/4885 |
| US-10793514-B2 | Glutamine transport inhibitors and methods for treating cancer | SLC1A5, SLC7A11, SLC3A2 | IDO1 2036/4885MAOB 2702/4885TAAR1 3015/4885 |
| US-10647683-B2 | Hsp70 modulators and methods for making and using the same | HSPA2, HSP90AA1, HSP90AB1 | IDO1 1909/4885MAOB 2862/4885TAAR1 4067/4885 |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | IDO1 4177/4885MAOB 415/4885TAAR1 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.